amgen glp 1 drug could threaten Novo Nordisk, Eli Lilly weight loss dominance Market Overview: GLP-1 Agonists and
Description
and A.L
[1,2] When overweight categories are included, the burden becomes even more striking: since 2022, approximately 40% of Canadian men and 30% of women are classified as overweight, meaning that nearly three in four men and two in three women fall within BMI ranges associated with increased health risk
Maybe so
This body of data suggests that there may be synergistic activity between GLP1 agonist and other metabolic pathway therapies
A percentage of people will not be able to tolerate the new pharmacotherapies or achieve the individualised goals and others may not have long-term access to these treatments
